Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



De novo designed lactoferrin–oleic acid-loaded chitosan nanoparticles with improved activity and selectivity toward four human cancer cells as compared to conventional complexes

Nawal Abd EL-Baky, Marwa Mohamed Abu-Serie, ELRashdy Moustafa Redwan.




Abstract
Cited by 2 Articles

Considering the oleic acid (OA) adverse effects on normal and cancer cells besides the less significant anticancer activities of free lactoferrins, this study aimed to formulate camel lactoferrin–OA or human lactoferrin–OA complexes-loaded chitosan nanoparticles that achieved cytotoxicity and apoptotic effect on four human cancer cells (Hela, HepG- 2, Caco-2, and MCF-7) while sparing normal healthy WI-38 cells. Cytotoxicity of these de novo nanoformulations was detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Their apoptotic effect was assessed using multiple staining; acridine orange, ethidium bromide, propidium iodide (PI), and annexin V besides the immunocytochemical nuclear staining protocol for Ki-67, Bcl-2, and p53. The increment in reactive oxygen species (ROS) manufacture was determined in treated cancer cell lines. Contrary to their corresponding complexes, nanocomplexes showed half maximal inhibitory concentrations (IC50) against tumor cells that were significantly (p < 0.05) lower than their safe doses (concentration achieving 100% cell viability, EC100) against WI-38, indicating their selective targeting of tumor cells. The nanoformulated complexes were more effective at inducing apoptosis and ROS increase in tumor cells than their corresponding complexes. A significant decrease in the levels of Ki-67 and Bcl-2 was found, while p53 level was increased in nanocomplexes-treated cancer cells. These findings suggest that nanoformulation of lactoferrin and OA potentiates their activity and selectivity toward cancer cells.

Key words: Anticancer, camel and human lactoferrins, nanocomplexes, oleic acid.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.